Breakthrough Animal Study for EVX-B1 Vaccine

Evaxion Biotech A/S and an unnamed collaborator reveal positive outcomes from animal trials of the EVX-B1 vaccine targeting Staphylococcus aureus, a bacterium causing severe health threats. The potential effectiveness of EVX-B1 antigens in human testing excites the company's Chief Scientific Officer, Birgitte Rønø, amidst rising antibiotic resistance in treating Staphylococcus aureus infections. Leveraging its AI-Immunology™ platform, Evaxion pioneers novel vaccines and immunotherapies for cancer, bacterial, and viral diseases.